Pfenex Inc (PFNX) Short Interest Update

Pfenex Inc (NYSEAMERICAN:PFNX) was the target of a significant increase in short interest in the month of March. As of March 29th, there was short interest totalling 206,985 shares, an increase of 38.4% from the March 15th total of 149,543 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average trading volume of 176,381 shares, the days-to-cover ratio is presently 1.2 days.

PFNX stock opened at $5.65 on Wednesday. Pfenex has a 12 month low of $2.07 and a 12 month high of $6.77.

How to Become a New Pot Stock Millionaire

Pfenex (NYSEAMERICAN:PFNX) last released its earnings results on Thursday, March 15th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.22 by $0.01. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. The firm had revenue of $17.91 million for the quarter, compared to analyst estimates of $5.00 million.

A number of equities analysts recently commented on PFNX shares. Zacks Investment Research raised shares of Pfenex from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Thursday, March 22nd. Barclays set a $8.00 price target on shares of Pfenex and gave the stock a “buy” rating in a research report on Thursday, March 29th. Finally, William Blair reaffirmed an “outperform” rating on shares of Pfenex in a research report on Friday, March 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. Pfenex has a consensus rating of “Hold” and a consensus price target of $7.67.

A number of hedge funds have recently added to or reduced their stakes in the business. Franklin Resources Inc. increased its holdings in Pfenex by 1.1% in the 4th quarter. Franklin Resources Inc. now owns 2,783,060 shares of the biotechnology company’s stock valued at $7,403,000 after buying an additional 31,295 shares during the period. Sanders Morris Harris LLC increased its holdings in Pfenex by 35.6% in the 4th quarter. Sanders Morris Harris LLC now owns 1,353,604 shares of the biotechnology company’s stock valued at $3,600,000 after buying an additional 355,453 shares during the period. Renaissance Technologies LLC increased its holdings in Pfenex by 26.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,010,600 shares of the biotechnology company’s stock valued at $2,688,000 after buying an additional 210,600 shares during the period. Millennium Management LLC increased its holdings in Pfenex by 61.3% in the 4th quarter. Millennium Management LLC now owns 359,288 shares of the biotechnology company’s stock valued at $956,000 after buying an additional 136,514 shares during the period. Finally, Deutsche Bank AG increased its holdings in Pfenex by 7.2% in the 4th quarter. Deutsche Bank AG now owns 332,060 shares of the biotechnology company’s stock valued at $883,000 after buying an additional 22,392 shares during the period.

ILLEGAL ACTIVITY NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/11/pfenex-inc-pfnx-short-interest-update.html.

Pfenex Company Profile

Pfenex Inc, a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial.

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply